Evidence map›Paper›PMID 39385859›Full record

ReviewCureus2024

Neuropharmacology of Neuropathic Pain: A Systematic Review.

Muhammad Umar Mian, Mishal Afzal, Aqsa A Butt, Muniba Ijaz, Kashaf Khalil, Maryam Abbasi, Marhaba Fatima, Mariam Asif, Saad Nadeem, Shivangi Jha and 1 more

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The role of combined adjuvant therapeutic drugs in modulating opioid dosage and pain status in cancer patients: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  2. Article
  3. A neuron-astrocyte signaling axis in the ACC sustains diabetic neuropathic pain.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Muhammad Umar MianInternal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Mishal AfzalInternal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Aqsa A ButtInternal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Muniba IjazInternal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Kashaf KhalilInternal Medicine, Jinnah Sindh Medical University, Karachi, PAK.
Maryam AbbasiMedicine, Darul Sehat Hospital, Karachi, PAK.
Marhaba FatimaInternal Medicine, People's University of Medical and Health Sciences for Women-Nawabshah, Nawabshah, PAK.
Mariam AsifInternal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Saad NadeemInternal Medicine, Allama Iqbal Medical College, Lahore, PAK.
Shivangi JhaObstetrics and Gynaecology, Pramukh Swami Medical College, Bhaikaka University, Anand, IND.
Binay K PanjiyarCardiology/Global Clinical Scholars Research Training, Harvard Medical School, Boston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuropathic pain, a debilitating condition, remains challenging to manage effectively. An insight into neuropharmacological mechanisms is critical for optimizing treatment strategies. This systematic review aims to evaluate the role of neuropharmacological agents based on their efficacy, involved neurotransmitters, and receptors. A manual literature search was undertaken in PubMed including Medline, Cochrane Library, Google Scholar, Plos One, Science Direct, and clinicaltrials.gov from 2013 until 2023. Out of the 13 included studies, seven evaluated the role of gabapentinoids. Two main drugs from this group, gabapentin and pregabalin, function by binding voltage-gated calcium channels, lowering neuronal hyperexcitability and pain signal transmission, thereby relieving neuropathic pain. Four of the pooled studies reported the use of tricyclic antidepressants (TCAs) including amitriptyline and nortriptyline which work by blocking the reuptake of norepinephrine and serotonin, their increased concentration is thought to be central to their analgesic effect. Three articles assessed the use of serotonin-norepinephrine reuptake inhibitors (SNRIs) and reported them as effective as the TCAs in managing neuropathic pain. They work by augmenting serotonin and norepinephrine. Three studies focused on the use of selective serotonin reuptake inhibitors (SSRIs), modulating their effect by increasing serotonin levels; however, they were reported as not a highly effective treatment option for neuropathic pain. One of the studies outlined the use of cannabinoids for neuropathic pain by binding to cannabinoid receptors with only mild adverse effects. It is concluded that gabapentinoids, TCAs, and SNRIs were reported as the most effective therapy for neuropathic pain; however, for trigeminal neuralgia, anticonvulsants like carbamazepine were considered the most effective. Opioids were considered second-line drugs for neuropathic pain as they come with adverse effects and a risk of dependence. Ongoing research is exploring novel drugs like ion channels and agents modulating pain pathways for neuropathic pain management. Our review hopes to inspire further research into patient stratification by their physiology, aiding quicker and more accurate management of neuropathic pain while minimizing inadvertent side effects.

Indexed as

analgesicsnerve painneuropathic painneuropharmacologyneurotransmitterspain modulationperipheral neuropathypharmacological treatmentsprismareceptors

Identifiers

PMID39385859
PMCPMC11464095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.